Share on Pinterest Wegovy resolved liver inflammation in nearly two-thirds of participants in a major clinical trial, twice the rate seen with placebo. Steve Christo-Corbis/Getty Images Wegovy ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in individuals aged 12 ...

How Long Does It Take for Wegovy To Work? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. When considering a weight loss medication — or any medication — it’s normal to ...

Semaglutide and tirzepatide aid weight loss by mimicking gut hormones Ozempic, Wegovy, Mounjaro and Zepbound treat diabetes, support weight loss The weight loss drugs differ in FDA-approved uses ...

Zepbound helped patients lose 50 pounds, compared to 33 pounds with Wegovy The study showed Zepbound users lost 20% of body weight Both drugs caused some mild stomach-related side effects MONDAY ...

MONDAY, May 12, 2025 (HealthDay News) — A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy.

the maker of the weight-loss drug Wegovy. San Francisco-based Hims & Hers said the plan was to make obesity care “more accessible, more affordable and more connected” for Americans.

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications.

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity medicine Wegovy came in below expectations in the first quarter of 2025.

Wegovy sales expected to recover after FDA ban on copycats Guidance for 2025 sales, profit both cut Slower US obesity market penetration Q4 sales narrowly miss, profits beat Shares up 3.4% ...